Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis

Rein Therapeutics announced that it has received orphan drug designation from the European Medicines Agency for LTI-03, its lead drug candidate aimed at preserving lung function in patients with idiopathic pulmonary fibrosis.